Microphysiological Systems (MPS) for Modeling Diabetes (UG3/UH3 Clinical Trial Not Allowed)
Funding Opportunity RFA-DK-17-035 from the NIH Guide for Grants and Contracts. NIDDK requests applications to join a new research consortium "Microphysiological Systems (MPS) for Modeling Diabetes (MPS-MOD)". NIDDK will support the development and validation of human tissue chips that closely mimic the normal physiology of key metabolic tissues, including the pancreatic islet, liver, skeletal muscle, and white adipose tissue (WAT). Experimental designs for the MPS-MOD platforms should incorporate strategies to measure pathophysiological changes associated with metabolic disease, including the impact of immune cells on m...
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 11, 2017 Category: Research Source Type: funding
Microphysiological Systems (MPS) for Modeling Diabetes (UG3/UH3 Clinical Trial Not Allowed)
NIDDK requests applications to join a new research consortium "Microphysiological Systems (MPS) for Modeling Diabetes (MPS-MOD)". NIDDK will support the development and validation of human tissue chips that closely mimic the normal physiology of key metabolic tissues, including the pancreatic islet, liver, skeletal muscle, and white adipose tissue (WAT). Experimental designs for the MPS-MOD platforms should incorporate strategies to measure pathophysiological changes associated with metabolic disease, including the impact of immune cells on metabolic dysfunction. Once developed, these multi-dimensional MPS-MOD platforms wi...
Source: NIDDK Funding Opportunities - December 11, 2017 Category: Endocrinology Source Type: funding
Translational Research in Pediatric and Obstetric Pharmacology and Therapeutics (R01 Clinical Trial Optional)
Funding Opportunity PAR-18-215 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to encourage applications for translational and clinical research as well as clinical trials that will advance our knowledge about the underlying mechanisms of drug action, response, and safety in children at various developmental stages, and in women during pregnancy and lactation. The overall goals of the FOA are to improve the safety and effectiveness of current drugs for pediatric or obstetric patients, and to enhance the development of new drugs or a safer usage of the existing d...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 28, 2017 Category: Research Source Type: funding
Translational Research in Pediatric and Obstetric Pharmacology and Therapeutics (R21 Clinical Trial Optional)
Funding Opportunity PAR-18-214 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to encourage applications for translational and clinical research as well as clinical trials that will advance our knowledge about the underlying mechanisms of drug action, response, and safety in children at various developmental stages, and in women during pregnancy and lactation. The overall goals of the FOA are to improve the safety and effectiveness of current drugs for pediatric or obstetric patients, and to enhance the development of new drugs or a safer usage of the existing d...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 28, 2017 Category: Research Source Type: funding
Discovery of Small Molecule Immunomodulators for Cancer Therapy (R01)
Funding Opportunity PAR-17-331 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to promote the discovery of novel small molecules that may enhance the ability of the immune system to selectively recognize and attack cancer cells. These small molecules could be further developed into stand-alone immunotherapeutics or synergistic partners for existing therapies, or as chemical probes for the discovery and validation of novel targets involved in anti-tumor immunity. Investigators from multiple scientific disciplines (immuno-oncology, tumor biology, screening technol...
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 20, 2017 Category: Research Source Type: funding
Using Small Molecules and Molecular Genetics to Identify Novel Targets and Mechanisms Contributing to Tumor Immune Evasion (R01)
Funding Opportunity PA-17-330 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity (FOA) is to stimulate research on the identification of new and novel targets and mechanisms involved in tumor immune evasion, which may be amenable to analysis by small molecules, pharmacological, or molecular genetics approaches. A specific focus of this FOA is to encourage cross disciplinary collaborations between immunologists, cell biologists, medicinal chemists, pharmacologists, and molecular biologists. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 20, 2017 Category: Research Source Type: funding
Translational Research in Pediatric and Obstetric Pharmacology and Therapeutics (R03)
Funding Opportunity ID: 292195 Opportunity Number: PAR-17-188 Opportunity Title: Translational Research in Pediatric and Obstetric Pharmacology and Therapeutics (R03)Opportunity Category: DiscretionaryOpportunity Category Explanation: Funding Instrument Type: GrantCategory of Funding Activity: HealthIncome Security and Social ServicesCategory Explanation: CFDA Number(s): 93.865Eligible Applicants: State governmentsCounty governmentsCity or township governmentsSpecial district governmentsIndependent school districtsPublic and State controlled institutions of higher educationNative American tribal governme...
Source: Grants.gov - March 3, 2017 Category: Research Tags: Health Income Security and Social Services Source Type: funding
Translational Research in Pediatric and Obstetric Pharmacology and Therapeutics (R21)
Funding Opportunity ID: 292197 Opportunity Number: PAR-17-187 Opportunity Title: Translational Research in Pediatric and Obstetric Pharmacology and Therapeutics (R21)Opportunity Category: DiscretionaryOpportunity Category Explanation: Funding Instrument Type: GrantCategory of Funding Activity: HealthIncome Security and Social ServicesCategory Explanation: CFDA Number(s): 93.17393.865Eligible Applicants: State governmentsCounty governmentsCity or township governmentsSpecial district governmentsIndependent school districtsPublic and State controlled institutions of higher educationNative American tribal go...
Source: Grants.gov - March 3, 2017 Category: Research Tags: Health Income Security and Social Services Source Type: funding
Translational Research in Pediatric and Obstetric Pharmacology and Therapeutics (R01)
Funding Opportunity ID: 292198 Opportunity Number: PAR-17-189 Opportunity Title: Translational Research in Pediatric and Obstetric Pharmacology and Therapeutics (R01)Opportunity Category: DiscretionaryOpportunity Category Explanation: Funding Instrument Type: GrantCategory of Funding Activity: HealthIncome Security and Social ServicesCategory Explanation: CFDA Number(s): 93.17393.865Eligible Applicants: State governmentsCounty governmentsCity or township governmentsSpecial district governmentsIndependent school districtsPublic and State controlled institutions of higher educationNative American tribal go...
Source: Grants.gov - March 3, 2017 Category: Research Tags: Health Income Security and Social Services Source Type: funding
Translational Research in Pediatric and Obstetric Pharmacology and Therapeutics (R03)
Funding Opportunity PAR-17-188 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to encourage applications for translational and clinical research as well as clinical trials that will advance our knowledge about the underlying mechanisms of drug action, response, and safety in children at various developmental stages, and in women during pregnancy and lactation. The overall goals of the FOA are to improve the safety and effectiveness of current drugs for pediatric or obstetric patients, and to enhance the development of new drugs or a safer usage of the existing d...
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 3, 2017 Category: Research Source Type: funding
Translational Research in Pediatric and Obstetric Pharmacology and Therapeutics (R21)
Funding Opportunity PAR-17-187 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to encourage applications for translational and clinical research as well as clinical trials that will advance our knowledge about the underlying mechanisms of drug action, response, and safety in children at various developmental stages, and in women during pregnancy and lactation. The overall goals of the FOA are to improve the safety and effectiveness of current drugs for pediatric or obstetric patients, and to enhance the development of new drugs or a safer usage of the existing d...
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 3, 2017 Category: Research Source Type: funding
Translational Research in Pediatric and Obstetric Pharmacology and Therapeutics (R01)
Funding Opportunity PAR-17-189 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to encourage applications for translational and clinical research as well as clinical trials that will advance our knowledge about the underlying mechanisms of drug action, response, and safety in children at various developmental stages, and in women during pregnancy and lactation. The overall goals of the FOA are to improve the safety and effectiveness of current drugs for pediatric or obstetric patients, and to enhance the development of new drugs or a safer usage of the existing d...
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 3, 2017 Category: Research Source Type: funding
Intramural NIGMS Postdoctoral Research Associate (PRAT) Program (Fi2)
Funding Opportunity ID: 288591 Opportunity Number: PAR-16-130 Opportunity Title: Intramural NIGMS Postdoctoral Research Associate (PRAT) Program (Fi2)Opportunity Category: DiscretionaryOpportunity Category Explanation: Funding Instrument Type: GrantCategory of Funding Activity: HealthCategory Explanation: CFDA Number(s): 93.859Eligible Applicants: State governmentsCounty governmentsCity or township governmentsSpecial district governmentsAdditional Information on Eligibility: Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply...
Source: Grants.gov - September 8, 2016 Category: Research Tags: Health Source Type: funding
Countermeasures Against Chemical Threats (CounterACT): Optimization of Therapeutic Lead Compounds (U01)
Funding Opportunity Number: PAR-16-331 Opportunity Category: DiscretionaryFunding Instrument Type: Cooperative AgreementCategory of Funding Activity: EnvironmentHealthCFDA Number: 93.11393.84693.85393.867Eligible Applicants State governmentsCounty governmentsCity or township governmentsSpecial district governmentsIndependent school districtsPublic and State controlled institutions of higher educationNative American tribal governments (Federally recognized)Public housing authorities/Indian housing authoritiesNative American tribal organizations (other than Federally recognized tribal governments)Nonpr...
Source: Grants.gov - June 15, 2016 Category: Research Tags: Environment Health Source Type: funding
Countermeasures Against Chemical Threats (CounterACT): Optimization of Therapeutic Lead Compounds (U01)
Funding Opportunity PAR-16-331 from the NIH Guide for Grants and Contracts. The mission of the NIH Countermeasures Against Chemical Threats (CounterACT) program is to develop new and improved therapeutics to treat and/or prevent injuries resulting from exposure to chemical threats. Chemical threats are toxic chemicals that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include traditional chemical warfare agents and toxic industrial chemicals and materials. This Funding Opportunity Announcement (FOA) requests research applications seeking support for...
Source: NIH Funding Opportunities (Notices, PA, RFA) - June 15, 2016 Category: Research Source Type: funding
